The Use of Technology to Improve MS Clinical Trials and Patient Care
NCT ID: NCT02454907
Last Updated: 2025-10-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
150 participants
INTERVENTIONAL
2018-07-31
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
NCT05949580
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
NCT00813969
Development of Digital Biomarkers in Multiple Sclerosis: Validation Study 2
NCT06309173
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
NCT00289978
MS Symptom Management Study
NCT02474940
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A further goal of this study is to determine if receiving periodic messages from the doctor's office, as well as having the direct contact information of a person in the office, improves the care of the patients and their experience thereof.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
One kind of communication with the clinic will be used.
Communication with the clinic
Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
Experimental
A different kind of communication with the clinic will be used.
Communication with the clinic
Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Communication with the clinic
Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Relapsing-remitting MS (2010 criteria)
* Expanded Disability Status Scale (EDSS) ≤6.0
* Possession of a smartphone OR of a mobile telephone with text messaging AND an e-mail account AND web access OR willingness to be provided with, and utilize, a smartphone for the duration of the study
* In the two years before screening:
at least two relapses, OR one relapse and two new lesions (unrelated to relapse symptoms) on magnetic resonance imaging (MRI), OR RRMS (MAGNIMS 2010 criteria) onset within the past year with no exposure to disease modifying therapies (DMT)
* Patient is starting one of the following MS therapies: injectable (subcutaneous interferon beta or glatiramer acetate) or oral (fingolimod, teriflunomide, or dimethyl fumarate) therapies
* Relapse and MRI activity occurred while untreated or despite one single treatment, and no change in therapy since that activity
* Lives within 100 miles of Johns Hopkins Medical Center (Baltimore, MD)
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Johns Hopkins University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ellen Mowry
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins University
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NA_00083614
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.